NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Antimicrobial Resistance and Modernising Microbiology > Large-scale COVID-19 infection and antibody test study launched

Large-scale COVID-19 infection and antibody test study launched

23 April 2020 · Listed under Antimicrobial Resistance and Modernising Microbiology, Clinical Informatics and Big Data, COVID-19

Some 20,000 households across England are being contacted to take part in the first wave of a major new government study to track the COVID-19 coronavirus in the general population.

Prof Sarah Walker

The study will help improve understanding around the current rate of infection and how many people are likely to have developed antibodies to the virus. Chief Investigator for the study is Sarah Walker, Professor of Medical Statistics and Epidemiology at the University of Oxford and the NIHR Oxford Biomedical Research Centre’s Co-theme Lead for Antimicrobial Resistance and Modernising Microbiology.

Participants in the study will form a representative sample of the entire UK population by age and geography. The results will help scientists and the government in the ongoing response to the coronavirus outbreak, with initial findings expected to be available in early May.

Led by the Department for Health and Social Care (DHSC) and the Office for National Statistics (ONS), the study draws on the world-leading scientific expertise of Prof Walker and her team, backed by the testing capabilities of data science company IQVIA UK and the National Biosample Centre in Milton Keynes. 

The flagship study forms part of Pillar 4 of the government’s COVID-19 testing strategy, to conduct UK-wide surveillance testing to learn more about the spread of the disease and help inform the development of new tests and treatments. It will add to the population data already being collected through the national surveillance programme operated by Public Health England, which has been enhanced since the end of February.

Prof Walker said: “This is one of the largest and most important studies under way into the COVID-19 virus and will transform our understanding of the infection. The University of Oxford is delighted to be the study sponsor.”

“In this study we want to work out how many people of different ages across the UK have Covid-19 now and how many have had Covid-19 in the past. We do this by testing for the virus in the nose and throat of people and by measuring levels of antibody in the blood.

“We also want to find out how many people have Covid-19 over time – either with symptoms or without knowing they have the infection because they don’t have any symptoms. We want to do this in a group of people that reflects the population of the UK, so a range of ages and places where people live.”

Health Secretary Matt Hancock said: “Understanding more about the rate of COVID-19 infection in the general population, and the longer-term prevalence of antibodies, is a vital part of our ongoing response to this virus.

“This survey will help to track the current extent of transmission and infection in the UK, while also answering crucial questions about immunity as we continue to build up our understanding of this new virus.

“Together, these results will help us better understand the spread of the virus to date, predict the future trajectory and inform future action we take, including crucially the development of ground-breaking new tests and treatments.”

Participants will provide samples taken from self-administered nose and throat swabs and answer a few short questions during a home visit by a trained health worker. The swab tests will show whether or not participants currently have the virus. They will be asked to take further tests every week for the first five weeks, then every month for 12 months.

In total, 25,000 people will take part in the pilot phase of the survey, with plans to extend it to up to around 300,000 over the next 12 months.

Adults from around 1,000 households will also provide a blood sample taken by a trained nurse, phlebotomist or healthcare assistant. These tests will help determine what proportion of the population has developed antibodies to COVID-19. Participants will be asked to give further samples monthly for the next 12 months.  

Swabs will be taken from all participating households, whether their members are reporting symptoms or not. Blood will not be taken in any households where someone has symptoms of COVID-19 or is currently self-isolating or shielding.

The trained study health workers will use all the recommended precautions to protect themselves and everyone in the household from getting the virus. Swab test results will be communicated back to participants by their GPs and confidentiality will be protected throughout the process. 

← BRC funds three further COVID-19 studies
Oxford COVID-19 vaccine begins human trial stage →

News

  • Classification system uncovers new information about ovarian cancers 18 January 2021
  • Ancient gene mutation found to cause rare hereditary condition 18 January 2021
  • Oxford study confirms medium-term impact of COVID-19 11 January 2021
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page